Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?

Author： Sovani Milind P Whale Christopher I Oborne Janet Cooper Sue Mortimer Kevin Ekström Tommy Tattersfield Anne E Harrison Timothy W

Publisher： Royal College of General Practitioners

ISSN： 1478-5242

Source： British Journal of General Practice, Vol.58, Iss.546, 2008-01, pp. : 37-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BackgroundPoor adherence with inhaled corticosteroids is an important problem in asthma management. Previous approaches to improving adherence have had limited success.AimTo determine whether treatment with a single inhaler containing a long-acting β₂-agonist and a corticosteroid for maintenance treatment and symptom relief can overcome the problem of poor adherence with inhaled corticosteroids.Design of studyRandomised, parallel group, open-label trial.SettingForty-four general practices in Nottinghamshire.MethodParticipants who used less than 70% of their prescribed dose of inhaled corticosteroid and had poorly controlled asthma were randomised to budesonide 200 μg one puff twice daily plus their own short-acting β₂-agonist as required (control group), or budesonide/formoterol 200/6 μg one puff once daily and as required (active group) for 6 months. The primary outcome was inhaled corticosteroid dose.ResultsSeventy-one participants (35 control, 36 active group) were randomised. Adherence with budesonide in the control group was approximately 60% of the prescribed dose. Participants in the active group used approximately 80% more budesonide than participants in the control group (448 versus 252 μg/day, mean difference 196 μg, 95% confidence interval 113 to 279; P<0.001) and were less likely to withdraw from the study (3 versus 13; P<0.01). No safety issues were identified.ConclusionUsing a single inhaler for both maintenance treatment and symptom relief approximately doubled the dose of inhaled corticosteroid taken, suggesting this could be a useful strategy to overcome the problems related to poor adherence with inhaled corticosteroids.